The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

CDG Therapeutics is a biotechnology company, that provides services, science and technology, significant opportunity for development, pipeline, intellectual property, numerous international patent applications, a spectrum of metastatic, solid tumors and progressive, pediatric central nervous system (CNS) malignancies, peptide drug prototypes and analogs, chemical synthesis.

Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

BioAffinity Technologies applies experience, intelligence and creativity to the global fight against cancer, the company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The company uses technology that preferentially targets cancer cells and cell types indicative of a sick condition to produce exclusive noninvasive diagnostic tests and cancer therapies. The business is engaged in the development of technologies that, in the future, will be able to diagnose, track, and treat a variety of cancers, including lung ailments. BioAffinity Technologies was established in 2014 in San Antonio, Texas.

Biomoda, Inc., a development state company, operates as an invitro diagnostics company that develops assays or tests to detect cancer. The company's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. It also involves in developing collection protocol and diagnostics for other cancers, including breast, oral, prostate, bladder, colorectal, and cervical. The company has an agreement with the New Mexico Institute of Mining and Technology through the New Mexico Department of Veterans Services for a clinical study for the early detection of lung cancer of the state's veterans. In addition, it has a collaborative agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in a clinical study. Further, the company has contracts with Quintiles Consulting and Alquest, Inc. who help to guide Biomoda through the FDA approval process. It has a strategic relationship with Obio. The company was founded in 1990 and is headquartered in Albuquerque, New Mexico.

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

Theryte Ltd. operated as a drug discovery and development company that is committed to bringing new cancer treatments to market. It also operated a virtual model for its discovery and development operations, outsourcing its chemistry, discovery biology and in vivo testing to a number of specialist commercial providers in Europe and North America. The company was founded by Hilmar Meek Warenius, Guenter Herbert Schmidt, Robert John Bishop and Robert Alexander Walker Johnstone on November 20, 1997 and headquartered in Keynsham, the United Kingdom.

Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs selected from its extensive portfolio with the potential to be safe and effective for improving patient care. The company’s product pipeline includes new uses for approved drugs and new molecular entities (“NMEs”) for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. Central to the company’s successful clinical development programs are its strong relationships with clinicians, academic medical centers, regional hospitals and specialized product and service providers. A phase II clinical development program is underway in addition to sponsored basic, translational and clinical research projects aimed at specific disease mechanisms. The company has built a robust portfolio of issued patents and pending patent applications on its products.

Hkg Epitherapeutics Ltd. is a private company headquartered in Hong Kong that operates research and development lab company.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Douglas Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products include acitretin capsules, anastrozole tablets, Azathioprine film-coated tablets, Clozapine tablets, Dutasteride, Quetiapinetablets and Rivastigmine capsules. The company was founded by Graeme Bruce Douglas in 1967 and is headquartered in Auckland, New Zealand.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

University Hospital Freiburg is a healthcare organization that offers research, education, clinical practice, and treatment programs. Freiburg University Medical Center ensures the possible care for their patients by bundling their knowledge from clinical practice, research, and teaching. Their scientific work aims at the responsible and at the same time rapid introduction of new therapies that save lives and maintain quality of life. Their university clinic offers the medical offspring limitless opportunities to expand their knowledge. It is founded in 1457 in Freiburg, Germany.